Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variation. Human leukocyte antigen (HLA) polymorphisms may influence immune response and disease outcome. We investigated the association of HLAII alleles with case definition symptomatic COVID-19, virus-specific antibody and T-cell immunity. A total of 1364 UK healthcare workers (HCWs) were recruited during the first UK SARS-CoV-2 wave and analysed longitudinally, encompassing regular PCR screening for infection, symptom reporting, imputation of HLAII genotype and analysis for antibody and T-cell responses to nucleoprotein (N) and spike (S). Of 272 (20%) HCW who seroconverted, the presence of HLA-DRB1*13:02 was associated with a 6·7-fold increased risk of case definition symptomatic COVID-19. In terms of immune responsiveness, HLA-DRB1*15:02 was associated with lower nucleocapsid T-cell responses. There was no association between DRB1 alleles and anti-spike antibody titres after two COVID vaccine doses. However, HLA DRB1*15:01 was associated with increased spike T-cell responses following both first and second dose vaccination. Trial registration: NCT04318314 and ISRCTN15677965.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111350 | PMC |
| http://dx.doi.org/10.1111/imm.13450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.
J Cyst Fibros
September 2025
Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Background: The long-term clinical consequences of COVID-19 in cystic fibrosis (CF) remain largely unexplored. This study aimed to assess the incidence of long COVID in a large population of people with CF.
Methods: This prospective, multicentre study enrolled individuals with confirmed SARS-CoV-2 infection between July 2021 and October 2022.
Post-COVID syndrome in symptomatic COVID-19 patients: a retrospective cohort study.
BMC Infect Dis
September 2025
Aix Marseille University, AP-HM, SSA, RITMES, Marseille, France.
Background: Although post-COVID symptoms have been documented in the literature, the risk factors and time required for full recovery remain unclear. We conducted a retrospective analysis of medical records of COVID-19 patients to investigate the prevalence of symptoms after an acute episode of COVID-19 and the risk factors for persistence of symptoms.
Methods: This retrospective cohort study analysis examined hospital records of post-COVID individuals with previously confirmed or probable SARS-CoV-2 infection and endurring symptom continuation for at least 3 months post-infection or presenting new symptoms persisting for at least 2 months.
Comparison of the ALKA and CRS scores to predict outcomes among patients with coronavirus disease 2019 infection in United Arab Emirates.
Front Med (Lausanne)
August 2025
Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Introduction: The coronavirus disease 2019 (COVID-19) pandemic resulted in significant global mortality and morbidity, with emerging mutant strains continuing to potentially precipitate severe respiratory illness. Two clinical assessment tools, namely, the COVID-19 Risk of Complications Score (CRS), based on 13 comorbidities, and the ALKA (age, lactate dehydrogenase, kidney function, and albumin) score have been developed to predict disease severity among patients who are symptomatic at presentation. This study aimed to compare the performance of these two risk-scoring systems in predicting hospital admission, critical illness, and mortality.
View Article and Find Full Text PDFCross-Reactivity of SARS-CoV-2 Antibodies With Typhoid Flagellar-H Protein.
Trop Med Int Health
September 2025
ImmunoCure - Center for Inflammatory Diseases, Karachi, Pakistan.
Background: Antigen cross-reactivity in infections may induce heterologous immunity, leading to immunological protection against widely divergent organisms. We hypothesised that this may be a factor in the varying intensity of COVID-19 infection globally.
Methods: During the COVID-19 pandemic, we tested 46 symptomatic patients for both COVID-19 antibodies and the Typhidot test.
Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
Vaccine
September 2025
International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPH), University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Background: This prospective study aimed to evaluate the dynamics and seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of vaccinated and unvaccinated health workers (HWs) in Bamako, Mali. The study also measured antibody responses as a function of SARS-CoV-2 infections, socio-demography, vaccination status and associated comorbidities.
Method: 685 vaccinated and 413 unvaccinated HWs (total = 1098) were monitored over a 15-month periods with follow-up visits every 3 months for the first 6 months and a final visit after 15 months.